Bannerbild German Brest Group - Forschung

Übersicht über Kongressbeiträge von 2015

Mitglieder der German Breast Group präsentierten im Jahr 2015 folgende Beiträge auf internationalen Kongressen:

14th St. Gallen International Breast Cancer Conference, 18 - 21 March 2015, Vienna, Austria 

Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M: 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015 10(3):211-9. 

DGHO, 9 - 13 October 2015, Basel, Switzerland

V. Möbus, HJ Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, EM. Grischke, H.G. Höffkes, P. Klare, YD. Ko, S. Schmatloch, N. Burchardi, S. Loibl, G. von Minckwitz: GAIN2: Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: results of the second safety interim analysis. DGHO 2015, Oral presentation

European Cancer Congress, 25 - 29 September 2015, Vienna, Austria

Untch M, von Minckwitz G, Gerber B , Eidtmann H, Rezai M, Fasching PA,Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S: Neoadjuvant chemotherapy with trastuzumab or lapatinib: survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). ECCO 2015, Oral presentation

Senologiekongress, 25 - 27 June 2015, Leipzig

V. Möbus, HJ Lück, H. Forstbauer, G. Wachsmann, A. Ober, A. Schneeweiss, B. Christensen, E. von Abel, EM. Grischke, H.G. Höffkes, P. Klare, YD. Ko, S. Schmatloch, N. Burchardi, S. Loibl, G. von Minckwitz: GAIN2: Adjuvante Phase III Studie zum Vergleich einer intensivierten dosisdichten adjuvanten Therapie mit EnPC im Vergleich zu einer dosisdichten, adaptierten Therapie mit dtEC-dtD bei Patienten mit einem frühen Hochrisiko-Brustkrebs: Ergebnisse der zweiten Sicherheitsanalyse. Senologie 2015, Oral presentation

Loibl S, Furlanetto J, Barinoff J, Bauerschlag D, Herr D, Lübbe K, Maass N, Müller V, Mundhenke C, Schmidt M, Schwedler K, Thill K, Gkantiragas I, Burchardi N, von Minckwitz G: DESIREE - Eine multizentrische, randomisierte doppelblinde, Phase-II-Studie zum Vergleich der Verträglichkeit bei vorgeschalteter ansteigender Everolimus Dosierung bei Patienten mit metastasiertem Brustkrebs. Senologie 2015, Poster

Loibl S, Majewski I, Guarneri V, Nekljudova V, McCormick Holmes E, Bria E, Denkert C, Eidtmann H, Sotiriou C, Loi S, Andre F, Untch M, Conte PF, Piccart-Gebhart M, von Minckwitz G, Baselga J; German Breast Group, Neu-Isenburg, Germany: Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. J Clin Oncol 33, 2015 (suppl; abstr 511)

Mueller V, Laakmann E, Fehm T, Moebus V, von Minckwitz G, Loibl S, Witzel I: Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. J Clin Oncol 33, 2015 (suppl; abstr TPS639)

Blank P, Loibl S, Linderholm BK, Caramuta S, Nekljudova V, Szucs TS, van Stiphout J, Ademi Z, von Minckwitz G, Schwenkglenks M: Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients. J Clin Oncol 33, 2015 (suppl; abstr e12079)

Furlanetto J, von Minckwitz g, Lederer B, Möbus V, Lueck HJ, Hanusch C, Thomssen C, Untch M, Loibl S: Death during study treatment: An evaluation of events in 31 German clinical trials. J Clin Oncol 33, 2015 (suppl; abstr 1036)

Krug D, Lederer B, Debus J, Blohmer JU, Costa SD, Eidtmann H, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Kümmel S, Paepke S, Schneeweiss A, Untch M, von Minckwitz G, Loibl S: Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. J Clin Oncol 33, 2015 (suppl; abstr 1008)

Savas PS, Salgado R, Caramia F, Denkert C, Loibl S, Sotiriou C, Andre F, Speed TP, Loi S: Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). J Clin Oncol 33, 2015 (suppl; abstr 613)

Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett SH, Zhang, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J Clin Oncol 33, 2015 (suppl; abstr LBA502)

Von Minckwitz G, Timms K, Untch M, Elkin EP, Fasching PA, Schneeweiss A, Salat C, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Eidtmann H, Paepke S, Reid JE, Nekljudova V, Hartman AR, Loibl S: Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 33, 2015 (suppl; abstr 1004)

Schneeweiss A, Moebus V, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Paepke S, Kümmel S, Tesch H, Untch M, Loibl S, von Minckwitz G: A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol 33, 2015 (suppl; abstr TPS1101)

IMPAKT, 7 - 9 May 2015, Brussels, Belgium

A. Sonnenblick , S. Brohée , R. Salgado , G. Van den Eynden , P. Neven , S. Loibl , C. Denkert , H. Joensuu, M. Piccart, C. Sotiriou: Constitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2. IMPAKT 2015, Poster

V. Müller, E. Laakmann, T. Fehm, V. Möbus, G. von Minckwitz, J. Kaiser, S. Loibl, I. Witzel: Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomaterial from breast cancer patients as platform for translational research. IMPAKT 2015, Poster

G. von Minckwitz, B. Pfitzner, V. Müller, P. Fasching, T. Karn, C. Schem, K. Schönfeld, T. Häder, S. Loibl, C. Denkert: Expression of CD138 / syndecan-1 in triple-negative breast cancer – correlative study of GeparSixto. IMPAKT 2015, Poster

S. Avril , G. von Minckwitz , K. Malinowsky , P. Fasching , T. Karn , A. Hartmann , M. Untch , C. Denkert, K.-F. Becker, S. Loibl: Phosphoproteomic assessment of HER2 signaling pathway in HER2 non-amplified patients of the GeparQuattro and GeparQuinto trials. IMPAKT 2015, Poster

P. Blank , S. Loibl , B. Linderholm , S. Caramuta , V. Nekljudova , T. Szucs , J. Van Stiphout , Z. Ademi, G. von Minckwitz, M. Schwenkglenks: Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer. IMPAKT 2015, Poster

S. Darb-Esfahani, W. Weichert, C. Denkert, G. von Minckwitz, V. Nekljudova, J. Lindner, V. Endris, F. Khandan, S. Loibl: p53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial. IMPAKT 2015, Poster

B. Pfitzner, S. Loibl, J. Lindner, P. Sinn, B. Lederer, S. Braun, K. Schmid, C. Denkert, G. von Minckwitz: Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studies. IMPAKT 2015, Poster


Poster presented at SABCS 2015

DESIREE

Loibl S, Furlanetto J, Barinoff J, Bauerschlag D, Herr D, Lübbe K, Maass N, Müller V, Mundhenke C, Schmidt M, Schwedler K, Thill M, Gkantiragas I, Burchardi N, von Minckwitz G

[OT1-03-08] DESIREE - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer. SABCS 2015, Poster

GAIN

Furlanetto J, Eiermann W, Marmé F, Reimer T, Reinisch M, Schmatloch S, Stickeler E, Thomssen C, Untch M, Denkert C, von Minckwitz G, Nekljudova V, Loibl S, Möbus V

[P1-13-04] Higher rate of severe toxicities in obese patients receiving dose-dense chemotherapy according to unadjusted body mass index – Results of the prospectively randomized GAIN study. SABCS 2015, Poster

GAIN-2

Möbus V, Lück H-J, Forstbauer H, Wachsmann G, Ober A, Schneeweiss A, Christensen B, von Abel E, Grischke E-M, Höffkes H-G, Klare P, Yon-Dschun K, Schmatloch S, Furlanetto J, Burchardi N, von Minckwitz G, Loibl S

[P1-13-05] GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses. SABCS 2015, Poster

NeoPHOEBE

Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Lee S-C, Turri S, Urban P, Kümmel S, Lux M, Piccart M, von Minckwitz G, Baselga J, Loi S

[P1-14-01] Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE. SABCS 2015, Poster

PIK3CA

Loibl S, Budczies J, Weichert W, Furlanetto J, Stenzinger A, Pfarr N, von Minckwitz G, Jackisch C, Schneeweiss A, Fasching P, Schmatloch S, Aktas B, Nekljudova V, Weber K, Untch M, Denkert C

[P3-07-03] PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study. SABCS 2015, Poster

GeparSepto

von Minckwitz G, Untch M, Jakisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Weibringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer J-U, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S

[P1-14-11] nab-paclitaxel at a dose of 125 mg/m2 weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69). SABCS 2015, Poster

INSEMA

MGMT

Fontanella C, Gehlhaar C, Denkert C, Schneeweiss A, Heppner B-I, Koch I, Blohmer J-U, Jackisch C, Lederer B, Fasching PA, Müller V, Untch M, Aprile G, Puglisi F, Nekljudova V, Heppner F, von Minckwitz G, Loibl S

[P3-07-55] Predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving carboplatin. SABCS 2015, Poster

FINESSE

Andre F, Daly F, Azim Jr HA, Agrapart V, Fumagalli D, Gingras I, Guitart M, Lange A, Turner NC, Pierrat M-J, Loibl S, Poirot C, Curigliano G, Loi S, Pallis A, Piccart M, Cortes J

[OT1-03-03] FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr. SABCS 2015, Poster

PALLAS

Mayer E, DeMichele A, Dubsky P, Barry W, Metzger O, Symmans WF, Burstein H, Miller K, Wolff A, Rastogi P, Loibl S, von Minckwitz G, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang Bartlett C, Chen L, Piccart M, Winer E, Gnant M

[OT1-03-21] PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. SABCS 2015, Poster

TNBC

Telli ML, McMillan A, Ford JM, Richardson AL, Silver DP, Isakoff SJ, Kaklamani VG, Gradishar W, Stearns V, Connolly RM, Loibl S, Elkin EP, Timms K, Hartman A-R, von Minckwitz G

[P3-07-12] Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis. SABCS 2015, Poster

GAIN

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F

[P3-07-28] BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study). SABCS 2015, Poster

Biomarker

Denkert C, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Mehta K, Müller V, Kammler R, Pfitzner BM, Fasching PA, Viale G

[P5-07-02] Systematic analysis and modulation of Ki67 interobserver variance in 9069 patients from three clinical trials – How much pathologist concordance is needed for meaningful biomarker results? SABCS 2015, Poster

BMBC

Witzel I, Loibl S, Laakmann E, Augustin D, Flock F, Dohmen H-H, Durmus G, Frank M, Hesse T, Ignatov A, Kühn T, Neunhöffer T, Park-Simon T-W, Schmidt M, Stefek A, Weide R, Würschmidt F, Fehm T, Moebus V, von Minckwitz G, Burchardi N, Mueller V

[P6-17-08] Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry. SABCS 2015, Poster

Kontakt

Lejla Valjevcic

Tel.: +4961027480418

Fax: +4961027480118

E-Mail: Pblctngbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd